Exchange: NASDAQ·Updated 07:30 PM EDT
ERAS logo

ERAS Erasca Inc

$15.55
$0.57
(3.69%)
Today
Closed $16.03
$0.48
(2.99%)
After Hours
EarningsNov 11
Mkt Cap$5.41B
Vol7.77M

About ERAS

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.
44

Bearish Sentiment

How do you feel about ERAS?

peloswing
$ERAS sitting at the bottom of a falling wedge formation, price is right on a horizontal zone from back in June, and it just tested + successfully defended its 200 DMA ✅ King node/positive gamma flip zone at $15 with more heavy positive gamma at $17.5, meaning if it can reclaim $15, we might see some volatility compression/chop/consolidation between $15 and $17.5 for a while next.
1
QuantInsider
$ERAS popped +9.49% today, adding to a +4.39% gain over the last five days But watch out, there’s a new legal investigation in play This makes chasing the breakout risky since any bad news could slam momentum Saw a 9,673-contract Nov 20 $17.5 call block at the ask on InsiderFinance, about $1.26M premium Shows some upside interest, but with the open interest and block structure, this is more of a reference point than a clear bullish signal Also saw late-day sweeps in $20 calls, 910 contracts, 29% OTM, with IV around 130% Feels like a volatility play more than anything Could be worth keeping an eye on

Advertisement|Remove ads.